Ordinary Fully Paid Deferred Settlement Market Cap ($2.62K)
Market Cap & Net Worth: Ordinary Fully Paid Deferred Settlement (IMUDA)
Ordinary Fully Paid Deferred Settlement market cap. Ordinary Fully Paid Deferred Settlement (AU:IMUDA) has a market capitalization of $2.62K (AU$3.70K) as of November 8, 2026. Listed on the AU stock exchange, this Australia-based company holds position #31957 globally and #1823 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ordinary Fully Paid Deferred Settlement's stock price AU$0.40 by its total outstanding shares 9249 (9.25K).
Ordinary Fully Paid Deferred Settlement Market Cap History (2025–2025)
Ordinary Fully Paid Deferred Settlement market cap history from 2025 to 2025. Data shows growth from $2.62K to $2.62K (0.00% CAGR). Check Ordinary Fully Paid Deferred Settlement share price for real-time trading data and today's change.
Ordinary Fully Paid Deferred Settlement Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ordinary Fully Paid Deferred Settlement's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of IMUDA by Market Capitalization
Companies near Ordinary Fully Paid Deferred Settlement in the global market cap rankings as of November 8, 2026.
Key companies related to Ordinary Fully Paid Deferred Settlement by market ranking:
- Chicken Soup for the Soul Entertainment, Inc. (NASDAQ:CSSEQ): Ranked #31948 globally with a market cap of $3.20K USD.
- Ordinary Fully Paid Deferred Settlement (AU:IXRDB): Ranked #31949 globally with a market cap of $3.12K USD ( AU$4.40K AUD).
- TOOSLA SA EO-08125 (F:W6Q): Ranked #31958 globally with a market cap of $2.58K USD ( €2.21K EUR).
- PureCycle Technologies Inc (NASDAQ:PCTTW): Ranked #31959 globally with a market cap of $2.58K USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #31948 | Chicken Soup for the Soul Entertainment, Inc. | NASDAQ:CSSEQ | $3.20K | $0.00 |
| #31949 | Ordinary Fully Paid Deferred Settlement | AU:IXRDB | $3.12K | AU$0.46 |
| #31958 | TOOSLA SA EO-08125 | F:W6Q | $2.58K | €0.00 |
| #31959 | PureCycle Technologies Inc | NASDAQ:PCTTW | $2.58K | $0.29 |
Market Capitalization of Ordinary Fully Paid Deferred Settlement (2025–2025)
Market capitalization of Ordinary Fully Paid Deferred Settlement from 2025 to today. Between 2025 and today, Ordinary Fully Paid Deferred Settlement's market cap moved from $2.62K to $ 2.62K, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | AU$2.62K | -- |
End of Day Market Cap According to Different Sources
On Jul 9th, 2026 the market cap of Ordinary Fully Paid Deferred Settlement was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.62K USD |
| MoneyControl | $2.62K USD |
| MarketWatch | $2.62K USD |
| marketcap.company | $2.62K USD |
| Reuters | $2.62K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ordinary Fully Paid Deferred Settlement
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA,… Read more